Close

Repros Therapeutics (RPRX) Discloses Negative Opinion From EMA for Enclomiphene

January 26, 2018 4:02 PM EST Send to a Friend
Repros Therapeutics Inc.®, (Nasdaq: RPRX) today announced that, consistent with the previously disclosed guidance ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login